FAMEFIX™ Drops

Cefixime is a third-generation oral cephalosporin that kills bacteria by inhibiting the final cross-linking step of peptidoglycan synthesis in the bacterial cell wall. It binds with high affinity to penicillin-binding proteins (PBPs) — specifically PBP1 and PBP3 — on the bacterial inner membrane, preventing transpeptidation and causing cell wall failure, osmotic instability, and bacterial lysis.

At 25mg per 5mL, FAMEFIX™ Drops delivers the lowest concentration cefixime formulation in the range, specifically calibrated for neonates, young infants, and very small children (typically 3–10 kg, ages 0–12 months) where even the standard 50mg/5mL dry syrup provides too high a dose per manageable volume. This ultra-low concentration allows accurate weight-based dosing — 8mg/kg/day — with volumes small enough for infant administration without the risk of vomiting from large liquid volumes.

Cefixime's third-generation cephalosporin characteristics — enhanced gram-negative spectrum, beta-lactamase stability against H. influenzae and M. catarrhalis enzymes, and excellent oral bioavailability (~40–50%) — are maintained at all concentrations, making this drops formulation clinically equivalent to higher-strength preparations in its breadth of antibacterial cover.

FAMEFIX™ Drops is designed for the youngest and smallest paediatric patients — neonates (above 6 months per safety guidelines), infants, and toddlers up to approximately 12 months — requiring cefixime therapy for the following conditions:

Acute Otitis Media: A primary indication in infants. Non-typeable H. influenzae and M. catarrhalis — both frequently beta-lactamase producers — are the dominant causative organisms. Cefixime drops are particularly indicated when amoxycillin has failed due to resistant organisms.

Urinary Tract Infections: E. coli and Klebsiella UTIs in infants — potentially serious at this age with risk of renal scarring if undertreated. Cefixime achieves high urinary concentrations at the 8mg/kg/day dose with reliable gram-negative cover.

Respiratory Infections: Bronchitis and mild community-acquired pneumonia in infants caused by susceptible H. influenzae and S. pneumoniae.

Enteric Fever: Typhoid fever in infants — cefixime is guideline-recommended for paediatric enteric fever management.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.